In this episode of SNL, we sat down with Eman Namati, former President and CEO of SpectraWAVE, which was acquired by Philips in early 2026. He now serves as Head of Advanced Imaging within Image Guided Therapy.

The SpectraWAVE HyperVue Imaging System provides high-resolution structural and molecular imaging to assess coronary arteries and plaque morphology.  The system also includes X1-FFR, allowing physiology assessment from a single X-ray angiographic view, without the need for a pressure wire. Together, they combine coronary anatomy, plaque characterization, and physiology to support PCI planning and optimization.

Eman previously spent a decade at NinePoint Medical, rising from principal scientist to CEO. Before that, he was a scientist conducting imaging and biomedical engineering research at Massachusetts General Hospital and the University of Iowa. Eman holds a PhD in Medical Imaging and Biomedical Engineering from Flinders University and completed postdoctoral research at Harvard Medical School.

In this interview, Eman discusses what scientists have to unlearn when they move into a CEO role, how a clear "North Star" shapes which MVP trade-offs to make at each company stage, and the difference between the evidence needed for regulatory clearance and commercial adoption.

If you'd rather read the summary of Eman's episode, head over here.

In this episode, we sat down with Paul Coletta, the co-founder and CEO of Vero Bioscience.

Vero's OrganAge™ assay measures the biological age of each organ from a single blood draw, and its Vero Compass platform turns that reading into a targeted action plan. 

Paul built his career on storytelling and consumer marketing, starting with a decade at Disney before leading brand and product marketing roles at MTV Networks, Nickelodeon, and Hewlett-Packard. He then went on to build popular food brands including Jamba Juice and Pinkberry, and spent a decade as CEO and Chairman of Urban Remedy.

In this interview, Paul explains why scientific validation isn't enough to bring a diagnostic to market. He also shares how Vero closed a $6 million seed round in just three weeks, what "patriots, not mercenaries" means when building a team, and the difference between asking a board for advice versus asking for permission.

If you'd rather read the summary of Paul’s episode, head over here.

In this episode, we sat down with Deanna Harshbarger, CEO of Cala Health.

Cala Health developed the Cala kIQ® System, a prescription wearable therapy for action hand tremor.

Deanna holds a degree in chemical engineering and brings more than 20 years of commercial medtech experience to Cala. Before joining the company, she held senior leadership roles at Johnson & Johnson, Boston Scientific, and Medtronic, and helped develop and commercialize technologies across interventional cardiology, neuromodulation, and diabetes care.

In this conversation, Deanna shares how she empowers leadership teams to execute, building clinical evidence step-by-step, how patient observation shapes product development, and why raising capital is both a sprint and a marathon.

In this episode, we sat down with Michael Mangano, President and CEO of ABK Biomedical. 

ABK’s Eye90 is an investigational Y90 radioembolization device for treating unresectable liver cancer.

Michael brings over 30 years of medical device experience, including 15 years at Boston Scientific in commercial and international leadership roles. He previously served as CEO of ReShape Medical and as President of the Americas for Sirtex Medical, scaling regional revenues from $34 million to over $130 million.

In this interview, Michael discusses the thinking behind ABK's pivot into Y-90 radioembolization, what it takes to execute a 120-patient pivotal trial while retaining ownership over the clinical function, how to build capabilities that competitors can't quickly catch up to, and why the player-coach culture gives startups an execution advantage.

In this episode, we sat down with we sat down with Murthy Simhambhatla, CEO of SetPoint Medical.

SetPoint is commercializing the first FDA-approved neuroimmune modulation implant for rheumatoid arthritis.

Previously, Murthy was CEO of Evolus, leading the company through its IPO, and held multiple leadership roles at Abbott, including President of Abbott Medical Optics and head of the company's Ibis Biosciences molecular diagnostics business. Earlier in his career, Murthy led development of Abbott's XIENCE drug-eluting stent platform following Abbott's acquisition of Guidant. Murthy holds a Ph.D. in Polymer Engineering and is a Fellow of the American Institute for Medical and Biological Engineering.

In this interview, Murthy discusses building commercial conviction years before launch, how to sequence platform indications around adjacent markets, and why SetPoint built its reimbursement function in-house rather than outsourcing it.

In this episode, we sat down with David Veino, President and CEO of Neuros Medical.

Neuros is commercializing the FDA-approved Altius Direct Electrical Nerve Stimulation System for chronic post-amputation pain.

Before Neuros, David held senior commercial leadership roles at Cardiovascular Systems (CSI) and Stryker, and helped grow CSI's coronary and peripheral business from approximately $50 million to more than $250 million in annual revenue while leading key amputation-prevention initiatives. He also serves as a private equity advisor with Sectoral Asset Management. 

In this interview, David discusses how commercialization begins by mapping the patient journey upstream, what it takes to generate gold-standard clinical evidence for a novel therapy, how investors assess scalable medtech businesses, and how to build an investor pitch that earns the next meeting.

In this episode of Medsider Radio, we sat down with David Veino, President and CEO of Neuros Medical.

Neuros is commercializing the FDA-approved Altius Direct Electrical Nerve Stimulation System for chronic post-amputation pain.

Before Neuros, David held senior commercial leadership roles at Cardiovascular Systems (CSI) and Stryker, and helped grow CSI's coronary and peripheral business from approximately $50 million to more than $250 million in annual revenue while leading key amputation-prevention initiatives. He also serves as a private equity advisor with Sectoral Asset Management. 

In this interview, David discusses how commercialization begins by mapping the patient journey upstream, what it takes to generate gold-standard clinical evidence for a novel therapy, how investors assess scalable medtech businesses, and how to build an investor pitch that earns the next meeting.  

Before we dive into the discussion, I wanted to mention a few things:

First, if you’re into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.

And if you’re ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.

These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.

If you'd rather read than listen, here's a link to the full interview with David Veino, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!

KEY MOMENTS FROM THE INTERVIEW

• (03:02) - David's 30-year medtech journey from cardiovascular devices to leading Neuros

In this episode of, we sat down with Vijit Sabnis, co-founder and CEO of Adaptyx Biosciences.

Adaptyx is a Stanford spinout developing wearable technology for continuous molecular monitoring.

Over the past 20 years, Vijit has worked at the intersection of deep technology as an inventor, founder, and investor. Before Adaptyx, he was a Partner at Khosla Ventures and co-founded Solar Junction to commercialize high-efficiency solar cell technology. He holds a Ph.D. in Electrical Engineering from Stanford.

In this interview, Vijit discusses how to recognize when a scientific idea is worth building a company around, how to build startup-style learning cycles when spinning technology out of academia, and designing products that are easy for clinicians and consumers to adopt. 

KEY MOMENTS FROM THE INTERVIEW

In this episode, we sat down with Bob Paulson, President and CEO of Sonex Health. 

Sonex’s UltraGuideCTR device is a minimally invasive technology that enables ultrasound-guided carpal tunnel release procedures to be performed outside the surgical suite using local anesthesia, expanding patient access and reducing the cost of care.

Before joining Sonex, Bob led multiple venture-backed medical device companies through commercialization, including NxThera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group. Earlier in his career, he held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, which was acquired by St. Jude Medical.

In this interview, Bob explains how to build a reimbursement strategy before your first clinical study, drive physician adoption when introducing a new care pathway, and raise capital aligned with value inflection points. 

KEY MOMENTS FROM THE INTERVIEW

In this episode, we sat down with Dr. Sudhir Srivastava, founder, chairman, and CEO of SS Innovations (Nasdaq: SSII). 

The company’s SSi Mantra surgical robotic system supports a variety of surgical robotic procedures, including cardiac surgery. 

Sudhir brings more than three decades of experience in minimally invasive and robotic cardiac interventions, having served as Director of Robotic Cardiac Surgery at the University of Chicago and founder of the International College of Robotic Surgery. A pioneer in the field, Sudhir has performed more than 1,400 robotic procedures, including over 750 beating-heart totally endoscopic coronary artery bypass (TECAB) surgeries.

In this interview, Sudhir discusses what it takes to democratize robotic surgery beyond affordability, how SS Innovations built teleproctoring, telesurgery, and the supporting infrastructure for its robotic platform, and his milestone-based approach to financing a capital-intensive medtech company. 

KEY MOMENTS FROM THE INTERVIEW